New stem cell transplant trial aims to treat sickle cell disease and other blood disorders

NCT ID NCT06872333

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a stem cell transplant from a donor for people with high-risk sickle cell disease, thalassemia, and other red blood cell disorders. Participants receive drugs and low-dose radiation before the transplant to help the new cells take hold. The study will track how well the transplant works and watch for side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant (from a donor) with alemtuzumab, thymoglobulin, and total body irradiation
What this could lead to: If successful, this could offer a long-term treatment option for people with severe sickle cell disease and other blood disorders, potentially reducing or eliminating the need for blood transfusions.
What could go wrong: This is an early phase 2 trial with only 62 participants, so results may not apply to everyone. There are serious risks like graft-versus-host disease, graft failure, and side effects from the drugs and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIAMOND-BLACKFAN ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha thalassemia spectrum beta-thalassemia major Diamond-Blackfan anemia hemoglobinopathy inherited hemoglobinopathy sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT FAILURE HEMOGLOBINOPATHIES SICKLE CELL DISEASE

Contacts and locations

Locations

Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.